BrightSpring Q1 Revenue Up 26% as Specialty Scripts Jump 30%, Acquisitions Add $79M
BTSG•BrightSpring reported Q1 revenue up 26%, fueled by a 30% jump in specialty pharmacy scripts and 28% Provider Services growth from Amedisys and LHC integrations adding $79M. Infusion saw double-digit acute and chronic specialty growth, while management forecast $606M in 2026 headwinds from IRA, specialty infusion and generic conversions.
1. Q1 Financial Performance
BrightSpring reported 26% revenue growth in Q1 2026, driven by a 30% increase in specialty pharmacy scripts and 28% expansion in Provider Services. Integration of Amedisys and LHC branches contributed $79 million to the quarter’s revenue.
2. Infusion Business Expansion
The infusion segment delivered double-digit growth across both acute and chronic specialty therapies, bolstered by the launch of a concierge program for IVIG and development of targeted therapy programs.
3. Strategic Acquisitions and Leverage Position
Management highlighted flexibility to pursue larger M&A while maintaining leverage in the mid-2x range, focusing on disciplined geographic expansions and tuck-in acquisitions aligned with long-term objectives.
4. Revenue Headwinds and Outlook
BrightSpring expects approximately $606 million of 2026 revenue headwinds, including $175 million from IRA impacts, $181 million from specialty infusion pressures, and $250 million from brand-to-generic conversions, with a goal to stabilize gross profit per script.
